A recent study has shown that patients with relapsed or refractory chronic lymphocytic leukemia may prolong their progression-free survival after treatment with a specific combination regimen. READ MORE

Conferences

The FDA just announced that it will allow marketing of the first agency-authorized test for use with flow cytometry in order to help in the detection of several leukemias and lymphomas.

READ MORE

Adolescent and young adult survivors of Hodgkin lymphoma may not be receiving the recommended post-treatment care.

READ MORE

News

A recent study has shown that patients with relapsed or refractory chronic lymphocytic leukemia may prolong their progression-free survival after treatment with a specific combination regimen.

READ MORE

Researchers have developed a novel prognostic assay that identifies patients with Hodgkin lymphoma with unfavorable post-ASCT outcomes after relapse.

READ MORE

The U.S. Food and Drug Administration said on Thursday it has approved Bayer AG’s treatment for follicular lymphoma, a cancer of the lymph system.

READ MORE

Jennifer R Brown, MD, PhD, presented the emerging treatments and management options for front line and relapsed or refractory chronic lymphocytic leukemia today at the Clinical Pathways Congress.

READ MORE

Research in Review

A recent study suggests a variable that should be used as a standard outcome measure for clinical trials of patients with follicular lymphoma.

READ MORE

Recent research in the Journal of Clinical Oncology examined outcomes for patients with myeloid malignancies who had vitamin D deficiency before undergoing allogeneic stem cell transplantation.

READ MORE

Addition of a multi-targeted kinase inhibitor to standard chemotherapy improves outcomes in patients with acute myeloid leukemia and a specific mutation.

READ MORE

Single-agent immunotherapy in patients with a subtype of diffuse large B-cell lymphoma provides more clinical benefit than conventional therapy.

READ MORE